BACKGROUND: Despite reduced perioperative mortality and routine use of adjuvant therapy following pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), improvement in long-term outcome has been difficult to ascertain. This study compares outcomes in patients undergoing resection for PDAC within a single, high-volume academic institution over two sequential time periods. METHODS: Retrospective review of patients with resected PDAC, in two cohorts: period 1 (P1), 1991-2000; and period 2 (P2), 2001-2010. Univariate and multivariate analyses using the Cox proportional hazards model were performed to determine prognostic factors associated with long-term survival. Survival was evaluated using Kaplan-Meier analyses. RESULTS: A total of 179 pancreatectomies were performed during P1 and 310 during P2. Perioperative mortality was 6.7 % (12/179) in P1 and 1.6 % (5/310) in P2 (p = 0.003). P2 had a greater number of lymph nodes resected (17 [0-50] vs. 7 [0-31]; p < 0.001), and a higher lymph node positivity rate (69 % [215/310] vs. 58 % [104/179]; p = 0.021) compared with P1. The adjuvant therapy rate was 30 % (53/179) in P1 and 63 % (195/310) in P2 (p < 0.001). By multivariate analysis, node and margin status, tumor grade, adjuvant therapy, and time period of resection were independently associated with overall survival (OS) for both time periods. Median OS was 16 months (95 % confidence interval [CI] 14-20) in P1 and 27 months (95 % CI 24-30) in P2 (p < 0.001). CONCLUSIONS: Factors associated with improved long-term survival remain comparable over time. Short- and long-term survival for patients with resected PDAC has improved over time due to decreased perioperative mortality and increased use of adjuvant therapy, although the proportion of 5-year survivors remains small.
BACKGROUND: Despite reduced perioperative mortality and routine use of adjuvant therapy following pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), improvement in long-term outcome has been difficult to ascertain. This study compares outcomes in patients undergoing resection for PDAC within a single, high-volume academic institution over two sequential time periods. METHODS: Retrospective review of patients with resected PDAC, in two cohorts: period 1 (P1), 1991-2000; and period 2 (P2), 2001-2010. Univariate and multivariate analyses using the Cox proportional hazards model were performed to determine prognostic factors associated with long-term survival. Survival was evaluated using Kaplan-Meier analyses. RESULTS: A total of 179 pancreatectomies were performed during P1 and 310 during P2. Perioperative mortality was 6.7 % (12/179) in P1 and 1.6 % (5/310) in P2 (p = 0.003). P2 had a greater number of lymph nodes resected (17 [0-50] vs. 7 [0-31]; p < 0.001), and a higher lymph node positivity rate (69 % [215/310] vs. 58 % [104/179]; p = 0.021) compared with P1. The adjuvant therapy rate was 30 % (53/179) in P1 and 63 % (195/310) in P2 (p < 0.001). By multivariate analysis, node and margin status, tumor grade, adjuvant therapy, and time period of resection were independently associated with overall survival (OS) for both time periods. Median OS was 16 months (95 % confidence interval [CI] 14-20) in P1 and 27 months (95 % CI 24-30) in P2 (p < 0.001). CONCLUSIONS: Factors associated with improved long-term survival remain comparable over time. Short- and long-term survival for patients with resected PDAC has improved over time due to decreased perioperative mortality and increased use of adjuvant therapy, although the proportion of 5-year survivors remains small.
Authors: T Bardol; G Subsol; M-J Perez; D Genevieve; A Lamouroux; B Antoine; G Captier; M Prudhomme; M M Bertrand Journal: Surg Radiol Anat Date: 2018-03-31 Impact factor: 1.246
Authors: Alex B Blair; Richard A Burkhart; James F Griffin; James A Miller; Matthew J Weiss; John L Cameron; Christopher L Wolfgang; Jin He Journal: J Surg Res Date: 2017-07-03 Impact factor: 2.192
Authors: Neda Amini; Gaya Spolverato; Rohan Gupta; Georgios A Margonis; Yuhree Kim; Doris Wagner; Neda Rezaee; Matthew J Weiss; Christopher L Wolfgang; Martin M Makary; Ihab R Kamel; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2015-04-30 Impact factor: 3.452
Authors: Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee Journal: J Gastrointest Surg Date: 2016-10-24 Impact factor: 3.452
Authors: D J Kagedan; M E Dixon; R S Raju; Q Li; M Elmi; E Shin; N Liu; A El-Sedfy; L Paszat; A Kiss; C C Earle; N Mittmann; N G Coburn Journal: Curr Oncol Date: 2016-10-25 Impact factor: 3.677
Authors: Daniel J Kagedan; Ravish S Raju; Matthew E Dixon; Elizabeth Shin; Qing Li; Ning Liu; Maryam Elmi; Abraham El-Sedfy; Lawrence Paszat; Alexander Kiss; Craig C Earle; Nicole Mittmann; Natalie G Coburn Journal: HPB (Oxford) Date: 2016-02-09 Impact factor: 3.647
Authors: Amer H Zureikat; Joal D Beane; Mazen S Zenati; Amr I Al Abbas; Brian A Boone; A James Moser; David L Bartlett; Melissa E Hogg; Herbert J Zeh Journal: Ann Surg Date: 2021-05-01 Impact factor: 13.787